CardioSomaticsCardioSomaticsCardioСоматика2221-71852658-5707Eco-Vector4510910.26442/CS45109ArticlesСтатьиResearch ArticlePatient after myocardial infarction: how to reduce the risk of recurrent ischemic events?Пациент после инфаркта миокарда: как снизить риск повторного ишемического события?BarbarashO. LБарбарашОльга Леонидовна

д-р мед. наук, проф., дир. ФГБНУ НИИ комплексных проблем сердечно-сосудистых заболеваний, зав. каф. кардиологии и сердечно-сосудистой хирургии ГБОУ ВПО КемГМА

Olb61@mail.ruKaretnikovaV. NКаретниковаВиктория Николаевна

д-р мед. наук, проф. кардиологии и сердечно-сосудистой хирургии ГБОУ ВПО КемГМА, зав. лаб. патологии кровообращения ФГБНУ НИИ комплексных проблем сердечно-сосудистых заболеваний

KashtalapV. VКашталапВасилий Васильевич

канд. мед. наук, зав. лаб. патофизиологии мультифокального атеросклероза ФГБНУ НИИ комплексных проблем сердечно-сосудистых заболеваний, доц. каф. кардиологии и сердечно-сосудистой хирургии ГБОУ ВПО КемГМА

Scientific-Research Institute for Complex Issues of Cardiovascular DiseaseФГБНУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеванийKemerovo State Medical Academy of the Ministry of Health of the Russian FederationГБОУ ВПО Кемеровская медицинская академия Минздрава России1506201562NO2 (2015)ТОМ 6, №2 (2015)121924092020Copyright ©; 2015, Eco-VectorCopyright ©; 2015, ООО "Эко-Вектор"2015Eco-VectorООО "Эко-Вектор"https://creativecommons.org/licenses/by-nc-sa/4.0https://cardiosomatics.ru/2221-7185/article/view/45109

The review article highlights concerns related to a low survival rate in patients after myocardial infarction (MI) and factors affecting it. The pivotal role is given to the issue of patient adherence to therapy after acute coronary events. The options to improve it as well as mechanisms to optimize medical therapy for patients after myocardial infarction, particularly the need for prolonged dual antiplatelet therapy (DAPT), have been identified. The rationale for changing the current guidelines for the management of patients with acute coronary syndromes (ACS) is based on the findings of the recently completed international clinical trial PE- GASUS-TIMI 54 with ticagrelor (Brilinta®), utilized as part of a DAPT regimen, that have demonstrated the efficacy and safety of DAPT prolongation after 12-month period in post-MI patients.

В обзорной статье обсуждены проблемы низкой выживаемости пациентов после перенесенного инфаркта миокарда (ИМ), а также факторы, влияющие на этот показатель. Обозначена в качестве приоритетной проблема приверженности пациентов терапии после перенесенного острого коронарного события, определены возможности ее улучшения, а также перспективны оптимизации медикаментозного лечения пациента после ИМ, в частности, необходимость пролонгированной двойной антитромботической терапии (ДАТТ). Обоснованием для изменения текущих рекомендаций по ведению пациентов с острыми коронарными синдромами могут быть результаты недавно закончившегося международного клинического исследования PEGASUS-TIMI 54 c тикагрелором (Брилинта®) в качестве второго компонента ДАТТ, продемонстрировавшие эффективность и безопасность пролонгации ДАТТ после 12 мес постинфарктного периода.

prevention of myocardial infarctiondual antiplatelet therapyticagrelorпрофилактика инфаркта миокардадвойная антитромбоцитарная терапиятикагрелорБойцов С.А. Профилактика неинфекционных заболеваний в стране: от «что делать» к «как делать». Профилактическая медицина. 2012; 2: 3-10.Россия 2014: Стат. справочник. Р76 Росстат. М., 2014.Mathers C.D, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PloS Med 2011; 3: e442.Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur Heart J 2013; 34: 3028-34.Sanfelix-Gimeno G, Peiro S, Ferreros I et al. Adherence to evidence - based therapies after acute coronary syndrome: a retrospective population - based cohort study linking hospital, outpatient, and pharmacy health information system in Valencia, Spain. JMCP 2013; 3 (19): 247-57.Kostis W.J, Deng Y, Pantazopoulos J.S et al. For the MIDAS14 Study group. Circ Cardiovascular Qual Outcomes 2010; 3: 581-9.Chung S.C, Gedeborg R, Nicholas O et al. Acute myocardial infarction: a comparison of short - term survival in national outcome registries in Sweden and in the UK. Lancet 2014; 383: 1305-12.Shah N.S, Huffman M.D, Ning H, Llloyd-Jones D.M. Trends in myocardial infarction secondary prevention: The National Health and Nutritional Examination Survey (NHANES), 1999-2012. J American Heart Association. 2015; 4: 1-12.Peeters A, Mamun A.A, Willekens F, Bonneux L for NEDCOM. A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J 2002; 23: 458-66.Smolina K, Wright F.L, Rayner M, Goldacre M.G. Long - term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovascular Qual Outcomes 2012; 5: 532-40.Bhatt D.L, Eagle K.A, Ohman E.M et al for the REACH Registry Investigators. JAMA. 2010; 304 (12): 1350-7.Jernberg T, Hasvold P, Henriksson M et al. Cardiovascular risk in post - myocardial infarction patients: nationwide real world data demonstrate the importance of long - term perspective. Eur Heart J doi: 10.1093/eurheartj/ehu505.Sorenzen R, Gislason G.H, Fosbol E.L et al. Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study. Br J Clin Pharmacol 2008; 66: 875-84.Gislason G.H, Rasmussen J.N, Abildstrom S.Z et al. Long - term compliance with beta - blockers, angiotensin - converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006; 27: 1153-8.Naderi S.H, Bestwick J.P, Wald D.S. Adherence to drugs that prevent cardiovascular disease: meta - analysis on 376162 patients. Am J Med 2012; 9 (125): 882-7.Fox K.A, Carruthers K.F, Dunbar D.R et al. Underestimated and under - recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J 2010; 31: 2755-64.Каретникова В.Н., Евсеева М.В., Калаева В.В и др. Почечная дисфункция при инфаркте миокарда с подъемом сегмента ST: факторы риска, влияние на прогноз. Сердце. 2014 (80); 6: 339-46.Каретникова В.Н., Зыков М.В., Кашталап В.В. и др. Значение почечной дисфункции для госпитального прогноза больных инфарктом миокарда с подъемом сегмента ST. Сердце. 2013 (73); 5: 50-6.Waters D.D, Schwartz G.G, Olsson A.G et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) substudy. Circulation 2002; 106: 1690-5.Cannon C.P, Braunwald E, Mc Cabe C.H. et al for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med 2004; 350 (15): 1495-504.Rex S et al. Immune versus thrombotic stimulation of platelets differentially regulates signalling pathways, intracellular protein - protein interactions, and alpha - granule release. Thromb Haemost 2009; 102: 97-110.Бурячковская Л.И., Сумароков А.Б., Учитель И.А., Гупало Е.М. Противовоспалительное действие клопидогрела при атеросклерозе. Рациональная фармакотерапия в кардиологии. 2011; 7 (6): 677-84.Solheim S et al. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. Thromb Haemost 2006; 96: 660-4.Chen Y.G et al. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chin Med J 2006; 119: 32-6.O,Gara P.T, Kushner F.G, Ascheim D.D et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task force on Practice Guidelines. Circulation 2013; 127 (4): e362-e425.Steg P.G, James S.K, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST- segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33: 2569-619.Wallentin L, Becker R.C, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.Husted S, Emanuelsson H, Heptinstall S et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double - blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038-47.Yusuf S, Mehta S.R, Zhao F et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003; 107: 966-72.Antman E.M, Wiviott S.D, Murphy S.A et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008; 51: 2028-33.Park S.J, Park D.W, Kim Y.H et al. Duration of antiplatelet therapy after implantation of drug - eluting stents. N Engl J Med 2010; 362 (15): 1374-82.Lee C.W, Ahn J.M, Park D.W et al. Optimal duration of dual antiplatelet therapy after drug eluting stent implantation: a randomized, controlled trial. Circulation 2014; 129 (3): 304-12.Valgimigli M, Campo G, Monti M et al. Short - versus long - term duration of dual antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012; 125 (16): 2015-26.Bhatt D.L, Flather M.D, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 47: 1982-8.Cavender M.A, Scirica B.M, Bonaca M.P et al. Vorapaxar in Patients With Diabetes and Prior MI: Findings from the TRA 2 P-TIMI 50 Trial. doi: 10.1161/CIRCULATIONAHA.114.013774.Chin C.T, Roe M.T, Fox K.A et al. Study design and rationale of a comparison of prasugrel andclopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 2010; 160: 16-22.Ong A.T, Mc Fadden E.P, Regar E et al. Late angiographic stent thrombosis (LAST) events with drug - eluting stents. J Am Coll Cardiol 2005; 45: 2088-92.Mauri L, Kereiakes D.J, Yeh R.W et al. Twelve or 30 months of dual antiplatelet therapy after drug - eluting stents. N Engl J Med 2014; 371: 2155-66.Giustino G, Baber U, Sartori S et al. Duration of dual antiplatelet therapy after drug - eluting stent impantation. J Am Coll Cardiol 2015; 65 (13): 1298-10.Gilard M, Barragan P, Noryani A.A et al. Six - month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non - resistant to aspirin: ITALIC, a randomized multicenter trial. J Am Coll Cardiol 2015; 65: 777-86.Эрлих А.Д. Двойная антитромбоцитарная терапия: необходимость приверженности к лечению и возможности ее повышения. Атеротромбоз. 2014; 2: 25-33.Bonaca M.P, Bhatt D., Cohen M et al for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long - term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. Doi: 10.1056/NEJMoa1500857.Bonaca M.P, Bhatt D, Braunwald E et al. Design and rationale for the prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin - thrombolysis in myocardial infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 2014; 167: 437-444.e5.Толпыгина С.Н., Полянская Ю.Н., Марцевич С.Ю. Лечение пациентов с хронической ИБС в реальной клинической практике по данным регистра ПРОГНОЗ ИБС (часть 2). Рациональная фармакотерапия в кардиологии. 2013; 9 (5): 49-9.